U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV …
FDA Approves First Vaccine for Pregnant Individuals to Prevent …
FDA approves Abrysvo for immunization at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory …
ABRYSVO | FDA - U.S. Food and Drug Administration
Oct 23, 2024 · ABRYSVO is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 …
FDA Approves Abrysvo to Treat Adults 18 to 59 Years of Age at …
Oct 23, 2024 · Abrysvo is the first RSV vaccine approved for adults aged 18-49 at increased risk for RSV-LRTD due to chronic conditions. The vaccine targets the RSV fusion protein, a major …
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ...
Aug 12, 2024 · Additionally and as previously announced, the U.S. Food and Drug Administration (FDA) has approved Pfizer’s supplemental Biologics License Application for the ACT-O-VIAL® …
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged …
Oct 22, 2024 · In August 2023, the FDA approved Abrysvo for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to 6 months of age by active immunization of …
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome …
5 days ago · The labeling for Abrysvo and Arexvy has been updated to include a warning regarding Guillain-Barré syndrome.
FDA clears Pfizer's Abrysvo as first maternal RSV vaccine
Aug 22, 2023 · Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower …
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
4 days ago · Abrysvo was first approved on May 31, 2023, for prevention of lower respiratory tract disease (LRTD) associated with RSV in adults aged 60 years or more, and has since been …
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Oct 23, 2024 · Following the latest FDA nod, Abrysvo has become the first and only RSV vaccine approved for adults who are younger than 50 years. Abrysvo is currently approved for the …